

Sacituzumab govitecan

Cat. No.:	HY-132254
CAS No.:	1491917-83-9
Target:	Antibody-Drug Conjugates (ADCs)
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	-80°C

Sacituzumab govitecan

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 25 mg/mL (Need ultrasonic)
----------	---

BIOLOGICAL ACTIVITY

Description	Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity ^[1] .
In Vivo	Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) produces significant antitumor effects in mice bearing human gastric cancer xenografts ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- J Control Release. 2024 Feb 13:367:779-790.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. *Bioconjug Chem.* 2015 May 20;26(5):919-31.
- [2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in *Oncotarget.* 2020 Mar 10;11(10):942]. *Oncotarget.* 2015;6(26):22496-22512.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA